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Abstract
Background: In developing countries rotavirus is the leading cause of severe diarrhoea and diarrhoeal
deaths in children under 5. Vaccination could greatly alleviate that burden, but in Mexico as in most low-
and middle-income countries the decision to add rotavirus vaccine to the national immunisation program
will depend heavily on its cost-effectiveness and affordability. The objective of this study was to assess the
cost-effectiveness of including the pentavalent rotavirus vaccine in Mexico's national immunisation
program.
Methods: A cost-effectiveness model was developed from the perspective of the health system, modelling
the vaccination of a hypothetical birth cohort of 2 million children monitored from birth through 60
months of age. It compares the cost and disease burden of rotavirus in an unvaccinated cohort of children
with one vaccinated as recommended at 2, 4, and 6 months.
Results: Including the pentavalent vaccine in the national immunisation program could prevent 71,464
medical visits (59%), 5,040 hospital admissions (66%), and 612 deaths from rotavirus gastroenteritis (70%).
At US$10 per dose and a cost of administration of US$13.70 per 3-dose regimen, vaccination would cost
US$122,058 per death prevented, US$4,383 per discounted life-year saved, at a total net cost of US$74.7
million dollars to the health care system. Key variables influencing the results were, in order of importance,
case fatality, vaccine price, vaccine efficacy, serotype prevalence, and annual loss of efficacy. The results are
also very sensitive to the discount rate assumed when calculated per life-year saved.
Conclusion: At prices below US $15 per dose, the cost per life-year saved is estimated to be lower than
one GNP per capita and hence highly cost effective by the WHO Commission on Macroeconomics and
Health criteria. The cost-effectiveness estimates are highly dependent upon the mortality in the absence
of the vaccine, which suggests that the vaccine is likely to be significantly more cost-effective among poorer
populations and among those with less access to prompt medical care – such that poverty reduction
programs would be expected to reduce the future cost-effectiveness of the vaccine.
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Worldwide, infection with rotavirus is the leading cause of
severe diarrhoea in children under age 5. Before age 5,
most children will have experienced an episode of rotavi-
rus gastroenteritis. Rotavirus infection may be either
asymptomatic or symptomatic. In the latter case, it is asso-
ciated with acute gastroenteritis, beginning with an acute
episode of watery diarrhoea, fever, and vomiting [1,2].
The diarrhoea lasts for an average of six days, although
cases have been reported in which it has lasted up to 20
days [3]. Rotavirus infection is typically more severe than
other common causes of childhood diarrhoea, and is
more likely to be associated with dehydration, hospitali-
sation, and death [1,4-6]. Some estimates have shown
that 20%–40% of all hospital admissions and 20% of
deaths from diarrhoea are attributable to rotavirus in chil-
dren under age 5 [4]. Every year, rotavirus causes approx-
imately somewhere between 352,000 and 592,000
deaths, 2 million hospital admissions, 25 million medical
visits, and 111 million cases of gastroenteritis requiring
only home care, in children under 5 years old [4]. As a
result, 1 out of 5 children with rotavirus gastroenteritis
will visit a physician; 1 out of 65 will be admitted to a hos-
pital; and approximately 1 out of 293 will die [4].
In temperate climates, rotavirus diarrhoea appears mostly
in winter, whereas in tropical climates seasonal patterns of
the disease are less evident [7] Incidence of rotavirus dis-
ease is similar among children in developed and develop-
ing countries. However, children in developing countries
have higher mortality rates due to several factors, includ-
ing less access to oral rehydration and a higher prevalence
of malnutrition. An estimated 1,205 children die from
rotavirus disease every day, and 82% of those deaths occur
among children in low-income countries. In fact, children
in low-income countries are nearly 3, 6 and 237 times as
likely to die from rotavirus as children in low middle,
upper middle and high income countries, respectively [4]
Therefore, the potential benefits of a rotavirus vaccine in
low-income countries and in the poorest parts of middle-
income countries such as Mexico could be very considera-
ble.
A new pentavalent rotavirus vaccine (PRV) for the preven-
tion of rotavirus gastroenteritis has been developed
(RotaTeq©, Merck). The vaccine contains five live bovine-
human reassortant serotypes (G1, G2, G3, G4, and
P1A[8]). The vaccine is given by mouth in a three-dose
schedule, starting at 6 weeks of age, with one- to two-
month intervals between doses. The vaccine has been
proven safe; and when the three-dose schedule is given, its
efficacy against G1–G4 rotavirus gastroenteritis of any
degree of severity is 74.0% (66.8 to 79.9% 95% CI),
whereas efficacy against severe G1–G4 gastroenteritis is
98.0% (88.3 to 100% 95% CI). Taking this into consider-
ation, this vaccine could prevent many of the deaths and
hospitalisations resulting from severe episodes of rotavi-
rus gastroenteritis.
Mexico, like many other low- and middle-income coun-
tries is currently facing decisions about whether and how
to incorporate newly available, expensive vaccines into its
national vaccination program. Just within the last two
years the government initially decided to make the mono-
valent vaccine available for a subset of counties with high
infant mortality rates and more recently decided to
expand vaccination to the entire country.
In most low- and middle-income countries the decision to
add a rotavirus vaccine to the national immunisation pro-
gram will depend heavily on the cost-effectiveness and
affordability of the vaccine. We present here a model
developed for such settings and projections from the
model using Mexican data.
Methods
Target population and perspective
A cost-effectiveness model was developed to inform the
decision about whether to include universal vaccination
with PRV in a national immunization program.
The cost-effectiveness analysis compares the cost of treat-
ment for rotavirus diarrhoea in the absence of a national
immunisation program with the cost of a national immu-
nisation program plus the cost of treatment for those cases
not averted by immunisation. Three doses of PRV would
be given by mouth during the first 6 months of life. Three
cost-effectiveness ratios are estimated: the incremental
cost of the program divided by (1) the number of cases
prevented, (2) the number of deaths prevented, and (3)
the life-years gained. Cost-effectiveness is estimated from
the perspective of the health care system, taking into
account both the medical costs associated with rotavirus
diarrhoea (as if all medical care costs were borne by the
system) and the costs of the immunisation program. Pro-
ductivity benefits and costs or savings that accrue to fami-
lies (e.g. transport and childcare) other than medical care
were not included.
In the application of the model to Mexico, an annual birth
cohort of two million children is assumed. Given the sea-
sonality of rotavirus disease, the birth cohort is divided
into 12 monthly sub-cohorts to distribute the births
throughout the year, assuming a constant number of
births per month. Costs are presented in 2006 dollars. All
future costs and health benefits are discounted at 3% in
the base case. Rotavirus-associated medical costs are esti-
mated for the first 5 years of life using age-specific inci-
dence by season for each event.Page 2 of 13
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The costs and benefits of implementing a national rotavi-
rus immunisation program were compared with a proba-
bilistic model using spreadsheet based software (@RISK
4.5.4; Pallisade, Newfield, NY) in EXCEL (Figure 1). The
model was analyzed under baseline conditions in order to
determine the costs of either option: immunizing at the
coverage levels of diphtheria and tetanus toxoids and per-
tussis (DTP) vaccine, or the prevailing situation, with no
vaccine. Key variables used in the model were varied using
univariate and probabilistic sensitivity analysis (see
Tables 1 through 4).
In this model the current practice with no vaccination is
compared with a vaccination program in which pentava-
lent rotavirus vaccine is included in a national childhood
immunisation program at current levels of coverage for
DTP. The vaccination program option represents inclu-
sion of PRV in a national immunisation program, for a
birth cohort of two million children (followed from birth
to 5 years of age) divided into 12 monthly sub-cohorts of
the same length. With a vaccination program, some chil-
dren may not be vaccinated, and because vaccine efficacy
is less than 100% against rotavirus diarrhoea, some vacci-
nated children also will become ill (Figure 1).
Given the perspective adopted in this study, the model
does not distinguish between children who do not
become ill with rotavirus diarrhoea and those who
become ill and do not use healthcare services (unless they
die). In other words, the model does not consider the
potential benefit associated with preventing cases of diar-
rhoea that are treated at home. In the diarrhoea arm of the
model are those who experience a medical visit, hospital-
isation, or death.
In this model the cohort is followed from birth to 5 years
of age and is allowed to have different incidence of rotavi-
rus medical visits, hospitalisations and deaths, according
to the month of the year and the age, in months, of the
children. The medical visits, hospitalisations and deaths
averted each month by the program correspond to the
reduction of incidence of each outcome due to serotype-
specific vaccine efficacy. The advantage of this approach is
that it enables the modelled benefits to reflect the lack of
vaccine benefit in reducing incidence prior to the first
dose, as well as different levels of protection after the first,
second and third doses. It also enables estimation of how
benefits can vary because of the seasonality of the inci-
dence of the virus. Once data become available in Mexico
on the real ages at which children receive the vaccine (as
compared to the ideal 2, 4, and 6 month vaccination
schedule modelled here) it will be possible to model the
expected reduction in benefit associated with delays in
vaccination.
The model inputs including disease burden, medical
costs, rotavirus serotypes prevalence, discount rate, effi-
cacy, coverage and price of the vaccine are shown in Tables
1 to 4.
Rotavirus disease: morbidity and mortality
Because the model estimates morbidity and mortality for
each monthly sub-cohort, it is possible to estimate the
expected number of cases, nationally, for each event in
each sub-cohort, by month and age, in order to consider
seasonal disease pattern as well as the seasonality of vac-
Table 1: Disease parameters
Monthly morbidity from rotavirus
diarrhoea as a percentage of diarrhoea
by all causes, 20021
Monthly morbidity from diarrhoea 
(per 100,000), 20032
Monthly mortality from diarrhoea 
(per 100,000), 20023
Under age 1 Under age 1 Age 1 to 4 Birth to age 5 Under age 1 Age 1 to 4 Birth to age 5
Jan 62.6 289.3 228.6 296.4 10.88 1.2 3.1
Feb 66.95 228.6 226.4 228.6 7.11 0.7 2
Mar 70.43 217.9 285.7 226.4 6.22 0.7 1.8
Apr 63.47 296.4 325 285.7 4.66 0.5 1.3
May 46.08 342.9 321.4 325 5.66 0.6 1.6
Jun 26.08 328.6 457.1 321.4 4 0.4 1.1
Jul 1.73 482.1 335.7 457.1 5.33 0.6 1.5
Aug 0.43 357.1 375 335.7 5.44 0.6 1.6
Sep 8.69 300 296.4 375 4.22 0.4 1.1
Oct 6.08 314.3 200 296.4 3.55 0.4 1
Nov 29.56 225 150 200 4.77 0.5 1.3
Dec 63.47 164.2 100 100 8 0.8 2.2
1/Source: InDRE (Institute for Epidemiologic Diagnosis and Reference)
2/Source: Health Ministry and SUIVE (Unified Information System for Epidemiological Surveillance)
3/Source: INEGI (National Institute National Institute of Statistics, Geography and Informatics)Page 3 of 13
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vaccine. In this way the model accounts for potential dif-
ferences in health benefit when a child is vaccinated just
before the beginning of the high-risk season or just after it
finishes. This is relatively unimportant for countries that
predominantly vaccinate children at routine well-baby
visits, but potentially quite significant for countries that
vaccinate with annual or semi-annual vaccination cam-
paigns.
The model assumes that serotype specific effectiveness of
PRV is constant within a country or region of interest. This
implies that the proportionate reduction of hospitalisa-
tions and outpatient visits for any particular serotype is
assumed to be the same everywhere. This is supported by
a recent analysis of the Rotavirus Efficacy and Safety Trial
(REST) by region [8]. However, there are large differences
among countries in the proportion of illness due to differ-
ent serotypes as well as differences in severity of illness
given underlying differences in nutritional and health sta-
tus as well an availability of prompt and effective care for
children with diarrhoea. Thus, use of the model in differ-
ent settings requires calibrating it to local serotype inci-
dence, and age-specific disease incidence and severity. In
Table 3 we present the prevalence of G1–G4 serotypes
specific for Mexico used in the model.
In the case of Mexico, nationally representative data are
available for diarrhoea incidence for 0 – 11 months of age
and for 12 – 59 months of age as well as the proportion of
diarrhoea in the 0 – 11 month group that is due to rotavi-
rus. However, there is no further breakdown by age of the
diarrhoea incidence for Mexico. The IMSS, the Mexican
Social Security system that cares for more than 30 percent
of the population, has data on incidence by month in the
first year of life and by year till age 5. Because the IMSS
population is wealthier on average than the non-IMSS
population, the overall incidence of severe disease is
lower, but the relative distribution of disease among the
months/years is probably similar to that in the general
Table 2: Health services utilization for children under 5 with diarrhoea
Hospital admissions Outpatient visits Total % requiring hospitalization
< 1 year 6,390 37,449 43,839 14.58%
1 year 4,250 110,805 115,055 3.69%
2 years 4,997 89,481 94,478 5.29%
3 years 2,367 56,810 59,177 4.00%
4 years 1,459 40,180 41,639 3.50%
Source: Instituto Mexicano del Seguro Social (IMSS), 2005
Table 3: Parameters used in the model
Baseline scenario Range for sensitivity analysis Source
Efficacy for the first year following vaccination (%)
Medical visits 87.7 (76.2–93.7) Vesikari T, et al, 2007
Hospital admissions 96.3 (91.1–98.5) Vesikari T, et al, 2007
Efficacy for the second year following vaccination (%)
Medical visits 73.8 (11.5–95.7) Vesikari T, et al, 2007
Hospital admissions 86.9 (10.8–99.7) Vesikari T, et al, 2007
Prevalence of G1–G4 serotypes (%) 90.0 (83–97) Mota-Hernandez, et al, 2003
Cost per medical visit) 2006 dollars) 35.85 (34.59–37.29) Nafate, 2005
Cost per hospital day (2006 dollars) 222.55 (215.13–229.97) Nafate, 2005
Cost of the vaccine per dose (2006 dollars) 10.00
Cost of administration for the whole schedule (2006 dollars) 13.77
Discount rate 3%
Life expectancy in years at age:
0 years 70.38 ‡
1 years 71.95 ‡
2 years 71.74 ‡
3 years 70.84 ‡
4 years 69.91 ‡
‡ CONAPO's own estimates. Mortality tables, 2002. Available at http://www.conapo.gob.mx/00cifras/proy/RM.xlsPage 4 of 13
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incident cases among the months of year 1 and amongst
the years 1–4 as required for the model (see Table 2).
There is also no information about how the proportion of
diarrhoea cases due to rotavirus changes with age in Mex-
ico. For children less than 1 year of age we only had the
overall proportion of diarrhoea due to rotavirus so we
used the distribution from the Marie-Cardine et al study
from France to impute the distribution across the 12
months [9]. This distribution is critical because it enables
quantification of changes in benefit associated with delays
in vaccination due, for example, to campaign vaccination
as opposed to routine vaccination. Mexican data are not
Schematic representation of the model for rotavirus immunisation program in MexicoFigure 1
Schematic representation of the model for rotavirus immunisation program in Mexico.
Table 4: Variables, values and distributions for the probabilistic sensitivity analysis
Variable Values Distribution
Reduction in outpatient visits Median 0.877 5th percentile 0.762 95th percentile 0.937 Beta
Reduction in hospitalization Median 0.963 5th percentile 0.911 95th percentile 0.985 Beta
Efficacy between the first and the third dose Median 0.726 5th percentile 0.574 95th percentile 0.828 Beta
Annual efficacy decrease Median 0.1 5th percentile 0.05 95th percentile 0.18 Beta
Outpatient visit cost Median 34.59 5th percentile 34.59 95th percentile 37.29 Gama
Hospitalization day cost Mean $252.52 ExponentialPage 5 of 13
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virus among children one year or older, thus we used the
proportions reported by Rivest et al from Canada, normal-
ised to the overall proportion due to rotavirus in Mexico
[10]. The normalisation was done comparing the overall
proportion due to rotavirus 0–12 mo in Canada with that
in Mexico.
Table 1 shows the monthly morbidity from rotavirus diar-
rhoea in children under age 1 as a percentage of all cases
of diarrhoea during 2002. The source for these estimates
was a study carried out in secondary- and tertiary-care sen-
try hospitals in 15 large cities across Mexico, with data
from 1996 through 2002 [11].
Data on the incidence and mortality associated with diar-
rhoea from all causes, as well as the fraction requiring
medical visits or hospital admission, obtained either
monthly or by age groups from various sources, are shown
in Tables 1 and 2.
In each monthly sub-cohort, representing infants born
during 2006, the expected numbers of medical visits, hos-
pital admissions and deaths attributable to rotavirus were
estimated for every month of life up to the age of 5 (60
months). These estimates were based on the specific inci-
dence by month and age group of events attributable to
rotavirus (see Tables 1 and 2). Even though rotavirus diar-
rhoea is reported to be more severe on average than the
other major causes of childhood diarrhoea, no Mexican
data are available on how the proportion attributable to
rotavirus differs among cases treated at home, cases
treated in ambulatory settings, cases hospitalized, and
deaths. The situation is further complicated by the fact
that initial infection with rotavirus is likely to be more
severe than subsequent infections, even by other serotypes
[12]. To the extent that this is true, then the relative sever-
ity of rotavirus is likely to fall with age. In absence of data,
we assumed that the proportion of diarrhoea cases due to
rotavirus was constant across health care settings.
Vaccine coverage levels, efficacy estimates, and 
prevalence of G1, G2, G3, and G4 serotypes in Mexico
The vaccine coverage for PRV is anticipated to be the same
as the one for the DTP vaccine, since both have a recom-
mended schedule of administration at 2, 4, and 6 months
of age. In 2004, the coverage of the full schedule of DTP
vaccine was 94% in children under age 1 [13]. In the base-
line scenario, we assume that the vaccine will be given
during the first 6 months of life as recommended, with the
three doses at 2, 4, and 6 months of age. Alternatively, to
see how sensitive the results are to delays in vaccination,
we estimated a scenario in which children are vaccinated
at 6, 8 and 10 months of age (maximum age permitted).
The efficacy estimates were taken from a clinical trial of
PRV [8], containing five live human-bovine reassortant
rotavirus strains (G1, G2, G3, G4, and P1A[8]). Efficacy
estimates in this study show an 87.7% reduction in office
visits from gastroenteritis caused by serotypes G1, G2, G3,
and G4 (95% CI, 76.2–93.7), and a 96.3% reduction in
hospital admissions from gastroenteritis caused by sero-
types G1, G2, G3, and G4 (95% CI, 91.1–98.5, Table 3).
Efficacy against deaths from rotavirus gastroenteritis is
assumed to be similar to efficacy in reducing hospitalisa-
tions. In the sensitivity analysis, the efficacy of the vaccine
was varied within the range of its confidence interval in
the clinical trial. These assumptions are conservative. The
emergency room visits were combined with outpatient
visits assuming the latter's efficacy, despite trial data sug-
gesting a greater reduction in the more severe disease
treated in emergency rooms because no information was
available on the number of emergency room visits in Mex-
ico. Similarly, one would expect deaths to be reduced
more than hospitalisations.
The aforementioned efficacy estimates correspond to the
first year starting 14 days after completion of the three
dose regimen. Efficacy estimates are also reported for the
second year, showing a slight decrease in protection
against the disease (Table 3). To take into account the like-
lihood of decreasing protection conferred by PRV against
rotavirus disease over time, and the lack of data on protec-
tion after the second year, the baseline scenario assumes
an annual 10% efficacy reduction from year three to five.
In the univariate sensitivity analysis, this percentage was
varied from 0 to 30%.
The vaccine clinical trials for PRV were powered to esti-
mate the protection conferred by the full vaccination
schedule and not the partial protection conferred after the
first or second dose. However, the model must consider
the effect of the vaccine before all three doses are admin-
istered. Two different efficacy estimates are available from
the clinical trial: that from the intent-to-treat analysis,
which includes all enrolled children, whether they
received the full vaccine schedule or not, and the per-pro-
tocol analysis which only considers those who received
the three doses per protocol. We considered the intent-to-
treat efficacy as the weighted average of the efficacy for full
schedule and the efficacy for partial schedule and used
that to estimate the effectiveness of a partial schedule. The
estimation procedure was as follows:
In algebraic terms we have:
EPP *(PPP/PITT)+X*(1-PPP/PITT) = EITT
Where:Page 6 of 13
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BMC Infectious Diseases 2008, 8:103 http://www.biomedcentral.com/1471-2334/8/103EPP = efficacy for the first year in the per-protocol study
PPP = subjects in the per protocol study
PITT = subjects in the intent-to-treat study
EITT = efficacy for the first year in the intent-to-treat study
X = efficacy between the first and the third dose, which is
the unknown variable we want to estimate
Note that PPP/PITT is the weight corresponding to the sub-
jects who received all three doses among all subjects
enrolled, and that (1-PPP/PITT) is the weight of those with
an incomplete immunisation schedule. This approach
doesn't provide information about how protection is dif-
ferent between the first and second dose from that
between the second and the third. We have assumed con-
stant effectiveness between the first and third dose.
Finally, the expression corresponding to the estimation is
X = (EITT-EPP *(PPP/PITT))/(1-PPP/PITT)
The reported efficacy estimates relate to protection against
disease caused by serotypes G1, G2, G3, and G4. To esti-
mate the potential reduction in the number of target
events (medical visits, hospitalisations, and deaths)
achieved by the vaccine, the fraction of rotavirus gastroen-
teritis attributable to serotypes G1, G2, G3, and G4 will be
taken into account; in Mexico, this figure is 90% [14]. In
the sensitivity analysis, this percentage was varied from 78
to 92%, to account for the range reported in the literature.
Cost estimates
Medical costs include the costs of outpatient visits and
hospital admissions, as well as the costs associated with
immunisation. To reflect the heterogeneity of the Mexican
Health System we considered the cost of illness estimated
for the main health institutions. We used the costs esti-
mated by Náfate-Martínez (2005) for the Ministry of
Health, the IMSS (Mexican Social Security Institute), and
private providers [15]. These system-specific estimates
were averaged by weighting each by the proportion of
people who receive treatment nationally from that sys-
tem. The estimate for the IMSS was assumed to be repre-
sentative of all social security institutions (it is by far the
largest). Table 3 shows data on the estimated costs per
outpatient visit and hospital day from gastroenteritis con-
verted into US dollars at 10.89 pesos per dollar the
exchange rate for September 8th, 2006. The average length
of a hospital stay was estimated to be five days. In the
probabilistic sensitivity analysis, cost per medical visit was
varied using a gamma distribution and the cost per hospi-
talization using an exponential distribution (Table 4). For
the univariate sensitivity analyses, the upper and lower
bounds of the 95% confidence interval were used.
For our baseline scenario, the price for each dose of the
vaccine was set at $10 dollars. Furthermore, the cost for
administering the full immunisation schedule, excluding
the vaccine itself, was assumed to be 150 Mexican pesos
and converted into US dollars at 10.89 pesos per dollar
the exchange rate for September 8th, 2006.
Given the chosen perspective, we have only considered
medical costs associated with either of the two alternatives
(immunisation and no immunisation). A further analysis
could encompass a societal perspective, including non-
medical costs for both alternatives, such as transportation
costs and productivity losses.
Life-years saved
Once the number of deaths preventable by immunisation
in our cohort was estimated, the life-years saved were also
estimated, based on the mortality tables published by
CONAPO (the Mexican National Population Council),
from which age-specific life expectancies were obtained
(Table 3) [16]. Life-years saved by the intervention were
calculated as the sum of deaths preventable at each age,
multiplied by life expectancy at that age, which were dis-
counted at a three percent rate.
Sensitivity analysis
Univariate sensitivity analysis
Starting from the baseline scenario, univariate sensitivity
analyses were carried out to examine the extent to which
the uncertainty in the variables affects our estimates. Con-
sidering that a market price for the vaccine has not been
set, a sensitivity analysis on this variable was also per-
formed. This makes it possible to anticipate cost-effective-
ness values for the program in a range of potential
scenarios of price per dose.
Given that the rotavirus case-fatality rate changes over
time (improvements in health care access, nutrition, pov-
erty alleviation programs, etc.), we performed a separate
analysis varying the actual case-fatality rate from 50% to
200% to see how sensitive the cost per life-year saved is
throughout these different contexts.
Probabilistic sensitivity analysis
To explore the robustness of the model and to estimate a
feasible variation range of the cost-effectiveness results we
conducted probabilistic sensitivity analyses and ran a
hundred thousand model iterations with random sam-
pling from the distributions.
For each of the uncertain variables in the model we
defined a range and distribution of variation for the prob-Page 7 of 13
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BMC Infectious Diseases 2008, 8:103 http://www.biomedcentral.com/1471-2334/8/103abilistic sensitivity analysis. Table 4 shows the variables
used in the probabilistic sensitivity analysis, their values
and assumed distributions.
Because the vaccine price has not yet been set by the man-
ufacturer, the model was also estimated for across a range
of possible prices from $5 to $15 dollars per dose.
Results
Baseline scenario
Our estimates suggest that if Mexican children were vacci-
nated as part of a national immunisation program, uni-
versal vaccination could prevent 71,464 medical visits
(59%), 5,040 hospital admissions (66%), and 612 deaths
from rotavirus gastroenteritis (70%) (Table 5). Medical
costs for rotavirus diarrhoea estimated for the cohort were
11.9 million dollars without the immunisation program.
Assuming a $10 dollar price per dose, the national immu-
nization program would cost $82.3 million dollars, and
would save $7.6 million dollars in medical costs. Thus,
the national immunization program would have a net
cost of $74.7 million dollars, leading to a net cost per
death prevented (or life saved) of $122,058 dollars and a
cost per discounted life-year saved of $4,283 dollars
(Table 5).
Univariate sensitivity analysis
The leading determinants of the cost-effectiveness results
were, case fatality, vaccine price, vaccine efficacy, serotype
prevalence, and annual loss of efficacy. When our model
was evaluated at the lower limit of the efficacy parameters,
the cost per life-year saved rose from $4,283 to $6,598
dollars (+54%), whereas at the upper limit, our cost-effec-
tiveness ratio falls to $3,969 dollars (-7.3%) per life-year
saved (Figure 2). The asymmetry reflects the fact that in
the base case the effectiveness is very high and has little
room to improve.
On the other hand, our estimates are less sensitive to the
medical costs of the disease. Varying the estimated costs
Table 5: Results in terms of health and costs, with and without the rotavirus vaccine program
Variable Without the program With the program Preventable by the vaccine
 (5th–95th percentile)*
% reduction
Medical visits 122,134 50,670 71,464
(68,135 – 74,432)
59%
Hospital admissions 7,585 2,545 5,040
(4,851 – 5,186)
66%
Deaths 871 259 612
(593 – 628)
70%
Life-years saved 43,411
(42,092 – 44,570)
Discounted Life-years saved 17,430
(16,888 – 19,908)
Medical costs (thousands of dollars)
For medical visits $ 4,046.74 $ 1,671.90 $ 2,374.84
(2,134 – 2,638)
59%
For hospital admissions $ 7,905.79 $ 2,649.22 $ 5,256.57
(293 – 17,825)
66%
Cost of the vaccine $ 56,400.00 -$56,400.00
(NA)
Cost of administration of the vaccine $ 25,895.32 -$25,895.32
(NA)
Total medical costs $11,952.53 $ 86,616.44 -$74,663.91
 (-79,624 – -62,049)
Cost per case prevented (dollars) $ 968.23
 (796 – 1,054)
Cost per hospitalization prevented 
(dollars)
$ 14,814.88
 (12,277 – 16,045)
Cost per death prevented (dollars) $122,058.40
 (101,113 – 131,226)
Cost per life-year saved (dollars) $ 1,719.93
 (1,424 – 1,848)
Cost per life-year saved 
(dollars, Discounted life-years)
$ 4,283.75
 (3,548 – 4,606)
* 5th to 95th percentile of the probabilistic estimatesPage 8 of 13
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+0.4% variation in the cost per life-year saved (Figure 2).
The results are very sensitive to the discount rate assumed
when calculated per life-year saved because all costs are
incurred in the first couple of years of life, but benefits
continue for a lifetime. The model is not sensitive to dis-
count rate when calculated per case of diarrhoea, hospital-
isation or death averted because the costs and benefits
occur concurrently.
When we calculated per life-year saved, our cost-effective-
ness estimates are highly sensitive to variations in case-
fatality rate. Assuming a case-fatality rate 50% lower than
the actual rate, the model yields a cost per life-year gained
of US$8,566 (a 100% increase), and assuming a case-
fatality-rate twice the actual rate, the cost per life-year
gained is US$2,142 (a 50% decrease) (Figure 3).
When assuming a scenario in which children are vacci-
nated at 6, 8 and 10 months of age, deaths averted fell to
501 (a 18% decrease), while the cost per discounted life-
year saved increased to US$5,292 (a 19% increase).
Probabilistic sensitivity analysis
For a price scenario of $10 dollars per dose we ran a hun-
dred thousand iterations using the parameter distribu-
tions defined in Table 4. The output for cost per
discounted life-year saved is graphed in Figure 4. Ninety
percent of the resulting cost-effectiveness estimates fell in
the interval of $3,548 to $4,606 dollars per discounted
life-year saved.
The results for the rest of the output variables are pre-
sented in brackets in Table 5 for the 5th and 95th percentile
of the estimates. Ninety percent of the estimated averted
deaths fell in the interval of 593 to 628. The same interval
for discounted life-years saved was 16,888 to 19,908 and
for net cost it was 62 to 79.6 million dollars.
Figure 5 presents the results of the same sensitivity analy-
sis conducted across the range of prices per dose. The
shaded area bounded by the dotted lines is the area in
which ninety percent of the estimates fall, for each price.
Given that there is no correlation between vaccine price
and the uncertainty of any of the other parameters, the
size of the interval does not vary with changes in price.
The horizontal line at $7,310 represents the 2005 Mexican
GNP per capita in US dollars, as point of reference.
Discussion
At prices below US $15 per dose, using base-case parame-
ter values, the cost per life-year saved is estimated to be
lower than one GNP per capita. This is a very conservative
estimate because it ignores the benefits associated with
preventing non-fatal cases of rotavirus, with the exception
of the savings in health care costs. Given the absence of
Univariate sensitivity analysisFigure 2
Univariate sensitivity analysis.Page 9 of 13
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that Mexico has already widely implemented a national
public health program using oral rehydration therapy to
reduce deaths from childhood diarrhoea, there was no
obvious alternative intervention against which vaccina-
tion can be compared. However, the WHO Commission
on Macroeconomics and Health suggested that interven-
tions are highly cost-effective if the cost per life-year saved
is lower than the per capita GDP; may be cost-effective if
their cost is less than two to three times the per capita
GDP; and are cost-ineffective if their cost is higher than
three times the per capita GDP [17]. This suggests that a
rotavirus immunisation program would be highly cost-
effective across a wide range of price-per-dose scenarios.
We estimated that delaying vaccination four months
could reduce by 18% the number of deaths prevented
with respect to vaccinating at the recommended ages. This
result gives us some lights of the expected reduction in
effectiveness for countries where most vaccination is con-
ducted in campaigns where delays are caused by waiting
till the next campaign.
The most common manner in which morbidity and mor-
tality are simultaneously considered is via cost-utility
analysis, using a measure of effectiveness such as quality
adjusted life years (QALYs). However, in the case of rota-
virus infection it would not be difficult to argue that the
impact of the illness on parental leisure and productivity
is a greater burden for households than the decrement in
the quality of life of the infant. As a result, a willingness to
pay study might be more useful for capturing the value of
Cost per discounted life-year saved (US dollars of 2006)Figure 4
Cost per discounted life-year saved (US dollars of 
2006).
Relationship between rotavirus case-fatality rate and cost per discounted life-year saved (US dollars of 2006)Figure 3
Relationship between rotavirus case-fatality rate and cost per discounted life-year saved (US dollars of 2006).Page 10 of 13
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ity analysis.
As with any vaccine, estimates of cost-effectiveness are
highly dependent upon the expected morbidity and mor-
tality in the absence of the vaccine. The estimates pre-
sented here reflect Mexican national averages in rotavirus-
associated morbidity and mortality. While the incidence
of infection with rotavirus is not strongly correlated with
socioeconomic status, the likelihood that an infection
results in severe dehydration requiring hospitalisation, or
in death, is strongly negatively correlated with socioeco-
nomic status. This suggests that the vaccine is likely to be
significantly more cost effective among poorer popula-
tions and among those with less access to prompt medical
care. It also suggests that poverty reduction programs,
nutritional support programs and the introduction of
health insurance programs for the poor, such as the ones
recently introduced in Mexico would be expected to
reduce the cost-effectiveness of the vaccine in the future.
As with any modelling exercise, the necessary simplifica-
tion of a complex reality implies limitations that must be
considered in the application of the results of the mode-
ling exercise to public policy. In almost every case the sim-
plifications reflected in this model would tend to
underestimate the true cost-effectiveness of the vaccine.
The exception is that the model does not consider possi-
ble vaccine side effects that might become apparent with
large-scale implementation of the vaccine even though
they were not observed in the clinical trial. Although none
of the clinical trials or post-market surveillance to date
suggest that this vaccine has significant vaccine-related
mortality or morbidity, there always exists the possibility
that a very low frequency side effect has not yet been
detected – as occurred with RotaShield. However, given
the high burden of Rotavirus disease in Mexico and other
developing countries, even if this were to occur it is very
unlikely to significantly alter the cost-effectiveness of the
new vaccine.
As mentioned above, the model does not consider the
impact of illness on parental productivity or the value to
households of averted illness. The cost of illness is likely
to be underestimated because it included outpatient and
inpatient costs, but did not separately estimate costs of
emergency care. In addition, the sample of facilities used
for costing did not include any tertiary-care facility.
Probabilistic sensitivity analysisFigure 5
Probabilistic sensitivity analysis.Page 11 of 13
(page number not for citation purposes)
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virus infection have average age-specific life expectancy.
To the extent that children who die of rotavirus are those
who are poorer and/or have less access to health services
and/or have other health problems including malnutri-
tion, then their life expectance may be shorter and the esti-
mated benefits optimistic. In an upper middle income
country such as Mexico, this bias is unlikely to be impor-
tant, especially because at almost any discount rate the
marginal difference in life expectancy is irrelevant. How-
ever in low income countries with high levels of compet-
ing infant mortality this is likely to be more important.
It is worth highlighting the fact that the estimates of cost
of administration and cost of illness are highly uncertain,
based on small-scale localised studies. Fortunately, they
are not major determinants of the resulting cost-effective-
ness estimates.
Finally, while such cost-effectiveness results are an essen-
tial input into the decision-making process, they are by no
means sufficient. For example, even though this model
considers differences in rotavirus mortality in populations
of different socio-economic status, it does not weigh the
distributional or equity implications of implementing
rotavirus vaccination. Because the intervention dispropor-
tionally benefits the poorest segments of the population,
a government that was seeking to reduce overall inequal-
ity in the population might give it higher priority than the
simple CE results would suggest. Similarly, political and
operational considerations are likely to be very important.
Conclusion
At prices below US $15 per dose, the cost per life-year
saved is estimated to be lower than one GNP per capita
and hence highly cost effective according to the suggested
criteria of the WHO Commission on Macroeconomics
and Health. Cost-effectiveness estimates are highly
dependent upon the case fatality in the absence of the vac-
cine, which suggests that the vaccine is likely to be signif-
icantly more cost effective among poorer populations and
among those with less access to prompt medical care –
suggesting also that poverty reduction programs would be
expected to reduce the cost-effectiveness of the vaccine in
the future. In other middle-income countries with similar
epidemiology (including case-fatality) the results are
likely to be similar. However, it is more difficult to extrap-
olate these conclusions to low income countries. On the
one hand, the case fatality is likely to be significantly
higher and the cost of administering the vaccine lower
because of lower labour costs (although in some countries
this will be outweighed by higher transport and logistics
costs), both of which would improve the vaccine's cost-
effectiveness. Whether this improvement in cost-effective-
ness is sufficient to compensate for the much lower ability
to pay will depend on the situation in a particular country.
As with any economic evaluation, caution should be exer-
cised in extrapolating the results to other settings. In this
case, the results of the modelling exercise are likely to be
most sensitive to differences in rotavirus case fatality rates
(see Figure 3) because these differ so much among devel-
oping countries. Vaccine efficacy is likely to vary relatively
little if administered as recommended, but poorer coun-
tries are less likely to be able to administer the vaccine at
2, 4 and 6 months, significantly reducing its effectiveness
in preventing infant deaths. Other potentially significant
factors include differences in cost of adding the vaccine to
the current regimen and differences in viral subtypes.
Finally, it is worth highlighting that while rotavirus vacci-
nation represents an opportunity to reduce the burden of
diarrhoeal disease in a cost-effective way in the short term,
medium to long term solutions such as interventions to
enhance health care seeking, education for oral rehydra-
tion therapy, health care infrastructure and nutrition
improvements, among others, could be highly cost-effec-
tive and should be promote by developing countries.
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